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THE ROLE OF GLP-1 RECEPTOR AGONIST AS A POTENTIAL TREATMENT 
FOR NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC 
STEATOHEPATITIS 
SARA BEHBAHANI 
ABSTRACT 
 Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver 
dysfunction in the western world and one of the main contributors to cirrhosis and 
potentially liver cancer and liver failure. A variety of behaviors and other factors can 
predispose certain individuals to an increased risk of developing NAFLD and non-
alcoholic steatohepatitis (NASH). These factors include, but are not limited to, obesity, 
insulin resistance, hyperglycemia, and high levels of fat in the blood. The result is the 
accumulation of fat in hepatocytes that over time leads to inflammation and scarring of 
the liver and ultimately liver damage. At present, the mainstay of therapy remains weight 
loss through dietary modification and lifestyle change. Due to the lack of specific 
targeted pharmacotherapies, there is great interest from the scientific community to find a 
potential therapy that can provide benefit to the many patients in need. Some existing 
medications, including pioliglitazones and angiotensin receptor antagonists, may be 
repurposed to help treat this condition. Vitamin E may improve the histology in NASH, 
but safety issues limit its use. Other drugs, such as farnesoid X receptor agonist, 
obeticholic acid, are also in clinical trials with great hope for the future. However, as the 
cause of NAFLD and thereby NASH is poorly understood, there is a need for further 
research in the field to better understand the pathophysiology of the disease and the 
		 vii 
potential for pharmacotherapy for treatment of the disease. There has, however, been 
evidence that the antidiabetic drug class known as glucagon-like receptor agonists (GLP-
1 RAs) has been shown to reduce liver damage in patients with non-alcoholic 
steatohepatitis. Liraglutide, currently a drug for type 2 diabetes and obesity, has been 
shown to provide great benefit in type 2 diabetes and obesity and after reviewing multiple 
studies, seems to provide a potential treatment also for patients with NAFLD and NASH. 
However, more research needs to be done to confirm this hypothesis. Its more potent 
version, called semaglutide, is currently in phase 2 clinical trials and provides great hope 
in potentially further reducing liver damage. This class of drugs provides a huge 
opportunity to address an unmet clinical need that could benefit millions of patients 
worldwide. 
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INTRODUCTION 
 
Liver Disease and Liver Failure 
 The term “liver disease” is non-specific and can be the result of many conditions 
including infections, immune system abnormality, genetics, cancers, and other causes 
such as alcohol abuse and fat accumulation (Liver Disease Causes, 2014). Liver disease 
causes damage to the liver, and over time the damage to the liver results in scarring 
(cirrhosis), which can lead to liver failure. A large portion of the liver must be damaged 
before liver failure occurs, a process that may develop rapidly or occur gradually over 
months or years. The complications that come with liver failure are grave and can be life 
threatening if not treated. Many patients with liver failure can be seen with jaundice, 
since they cannot break down bilirubin. They may bruise more easily due to the lack of 
clotting factor production. Toxic waste cannot be broken down, fluid may accumulate in 
the stomach (ascites), and many other complications can occur (Herrine, 2016). Although 
the liver has the ability to regenerate, excessive liver damage leading to liver failure may 
need to be treated by a liver transplant, a highly invasive surgical procedure, if the cause 
of the liver disease cannot be treated.   
Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis 
 One of the major causes of liver disease, and ultimately liver failure, is known as 
non-alcoholic fatty liver disease (NAFLD). NAFLD is now considered the most common 
liver disease in the western world (Ahmed, 2015). Twenty to 30% of the western world’s 
general population suffers from NAFLD, and it is even more prevalent in type 2 diabetics 
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(70%) and morbidly obese patients (30%). The disease is identified as the accumulation 
of excessive fat in the liver in the absence of excessive alcohol intake. NAFLD is 
clinically related to metabolic syndrome, with many patients suffering from obesity.  The 
disease remains asymptomatic most of the time, which makes it hard to diagnose. 
However, the disease can progress unnoticed from non-alcoholic steatosis (NAS) to non-
alcoholic steatohepatitis (NASH) and ultimately to hepatic fibrosis, cirrhosis, and liver 
failure. A variety of conditions can increase the risk of NAS. Table 1 is a list of the 
different categories and associate conditions. 
Table 1: Conditions Associated With NAFLD (Puri & Sanyal, 2012). 
• Insulin Resistance 
o Obesity 
o Sedentary lifestyle 
o Type 2 diabetes mellitus 
o Hypertension 
o Dislipidemia 
• Drugs 
o Tamoxifem 
o Corticosteroids 
o Amiodarone 
o Methotrexate 
o Estrogens 
o Valproic Acid 
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o Antiretroviral medications 
• Carbohydrate Excess(e.g. diet and total parenteral nutrition) 
• Rapid Weight Loss 
• Altered small bowel anatomy 
o Obesity surgery (jejunoileal bypass) 
o Pancreaticduodenal resection 
o Short gut 
• Metabolic diseases (resulting in a NASH-like histology) 
o Hypobetalipoproteinemia 
o Abetalipoproteinemia  
o Wilson’s disease 
o  Lipodystrophies Andersen disease  
o Weber-Christian syndrome 
• Infections 
o Chronic hepatitis C virus, mainly genotype 3  
o Human immunodeficiency virus and acquired immune deficiency 
syndrome 
• Emerging associations 
o Polycystic ovarian syndrome 
o Hypothyroidism 
o Obstructive sleep apnea 
o Hypopituitarism 
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o Hypogonadism 
Some of the risk factors associated with NAFLD are due to lifestyle and related to food 
intake and physical activity. Therefore, some ways to prevent NAFLD are to maintain a 
healthy body weight, eat a healthy diet, exercise regularly, and limit alcohol intake. Other 
risk factors such as diabetes or abnormally high low density lipoprotein (LDL) levels 
need medical intervention. Many of the risk factors for NAFLD are also common ones 
for cardiovascular disease. Thus, it is important to treat the root cause of the disease 
before it is too late for treatment and could lead to NASH and cirrhosis.  
The only current treatment of NAFLD is lifestyle modifications. Ten percent 
weight loss within six months is associated with improvement of the disease 
(Hekamatdoost, 2016). Moreover, the intake of dietary supplements such as Vitamin E 
and probiotics have been associated with some improvement. Interestingly, turmeric and 
cinnamon, as insulin sensitizers, increase the effectiveness of an improved diet or 
regimen. Additionally, anti-oxidants that have anti-inflammatory effects and reduce 
metabolic disturbances have also been shown to yield improvement in liver function 
(Faghighzadeh, Adibi, & Hekamatdoost, 2015). It seems that in addition to a healthy 
lifestyle, the addition of anti-oxidative, anti-inflammatory agents, and/or insulin 
sensitizing agents can help improve outcomes for patients with NAFLD. It would, 
thereby, make sense that current therapies, such as anti-obesity and anti-diabetics, which 
strive to regulate metabolism, could provide a better outlook for patients with NAFLD.  
		 	 5		
Glucagon-Like Peptide-1 (GLP-1) 
GLP-1 receptor agonist (GLP-1 RA) analogues are used to treat diseases such as 
diabetes and obesity, some of the conditions associated with NAFLD. GLP-1 RA 
analogues, such as liraglutide, exenetide, and albiglutide, are a widely used class of 
pharmacologic agents used for improvement of glycemic control in patients with type 2 
diabetes (Prasad-Reddy & Isaacs, 2015). More recently, liraglutide, has also been 
approved for use in obese patients with a body mass index (BMI) greater than 30 or a 
BMI of greater than 27 with at least one weight-related comorbidity such as hypertension, 
diabetes, or dyslipidemia (Nuffer & Trujillo, 2015). 
GLP-1 is a member of the “glucagon peptide family” and is derived from the 
expression of preproglucagon gene on chromosome 17. The production of the GLP-1 
protein is a multistep process outlined in Figure 1. GLP-1 is released from 
neuroendocrine L cells, and preproglucagon undergoes posttranslational processing in a 
tissue-specific manner. Human GLP-1 is susceptible to inactivation by cleavage at 
position 2 (alanine) by the endogenous enzyme known as ubiquitous dipeptidyl peptidase 
4 (DPP-4). The inactivation happens almost immediately after the time of release of the 
GLP-1 rendering a very short half-life of less than two minutes. Pharmacological agents 
on the market are therefore human protein analogues that have been modified to avoid 
degradation by enzymes. There are two main families of GLP-1 analogues: the exendin-
based therapies and human GLP-1 analogues. The exendin-based therapies are based on 
exendin-4, a naturally occurring peptide derived from the venom of the Gila monster, 
homologous to some extent to human GLP-1. It is resistant to DPP-4 mediated 
		 	 6		
inactivation. The human GLP-1 analogue family of GLP-1 receptor agonists includes 
smaller peptides with 90-97% amino acid similarity to the native GLP-1. These peptides 
are modified at the second amino acid position to be resistant to degradation by the DPP-
4 enzyme which prolongs the half-life and thereby the effects of the GLP-1 protein in 
vivo (Gupta, 2013). Moreover, these human GLP-1 analogues are often additionally 
modified by conjugating them to substances such as fatty acids, albumins, etc. in order to 
slow down renal clearance and further increase their half-life in vivo. Table 2 shows a list 
of current GLP-1 analogues on the market. 
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GLP-1 Endocrine Pathway 1:  The Production of GLP-1 (Gupta, 2013): Albiglutide 
is resistant to DPP-4 degradation due to an amino acid substitution (alanine at position 2 
to glutamic acid) 
  
Table 2: GLP-1 Receptor Agonists Currently Available And In Development 
(Gupta, 2013). 
 
Incretins, hormones that stimulate insulin secretion, like glucagon-like peptide 1 
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal 
peptide hormones regulating postprandial insulin release from pancreatic β-cells. GLP-1 
receptor agonism is a currently approved treatment strategy by the Food and Drug 
Administration (FDA) in the United States for type 2 diabetes mellitus, obesity, and is 
also being evaluated for NAFLD.   
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GLP-1-based therapies function through a multitude of ways including by 
increasing insulin release and decreasing glucagon release, slowing gastric emptying and 
reducing food intake (Baynes, 2010). Moreover, GLP-1 has also been shown to increase 
insulin sensitivity and to reduce fat absorption in the gut. Upon food consumption, there 
is an increase in concentration of GLP-1 leading to the reactions stated above. More 
recently, the GLP-1 receptor agonists have also been shown to reduce inflammation in 
vasculature as well as in various organs (Marso, et al., 2016). The mechanism of action of 
the GLP-1 protein is key to understanding its potential use as a therapeutic for a variety 
of diseases.  
GLP-1 receptor distribution is rather expansive. There are GLP-1 receptors found 
in the pancreas, lung, brain, stomach, heart, vasculature, kidney, and a variety of white 
blood cells such as macrophages and monocytes. GLP-1 receptors in the brain are found 
in the hypothalamus which is responsible for appetite control (Bataille, et al., 2017). 
Based on its distribution throughout the body, the GLP-1 receptor has been a target for 
pharmacological agents in an attempt to treat various conditions related to what is known 
as metabolic syndrome. Metabolic syndrome is the name for a group of risk factors, later 
described, that raises the risk for heart disease and other health problems such as diabetes 
and stroke (2016). The hepatic manifestation of metabolic syndrome is NAFLD. 
Studies have shown that GLP-1 analogues exert a variety of benefits within the 
cardiovascular system, neurological system, and the gastrointestinal/hepatobiliary system 
(Gupta, 2012). It is, therefore, of great interest to further analyze the potential effects of 
the GLP-1 analogues in related conditions such as NAFLD. 
		 	 9		
Liraglutide, a potent GLP1-RA, is approved for the treatment of obesity and 
diabetes.  Given its pharmacological properties, liraglutide presents a potential treatment 
option for patients with NASH in the future. More work needs to be done to confirm such 
a hypothesis, but future clinical trials involving the use of liraglutide in patients with 
NAFLD/NASH can deepen our understanding and provide definitive evidence of the 
effects of liraglutide on hepatic function with patients who have NAFLD/NASH. 
Specific Aims 
1. Comprehensively review the literature to characterize the pathophysiology of 
NAFLD 
2. Evaluate current strategies to diagnose and treat NASH and NAFLD 
3. Determine if current evidence supports the use of GLP-1 receptor agonists as an 
effective pharmacological treatment for NAFLD and NASH 
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CURRENT STATE OF NON-ALCOHOLIC FATTY LIVER DISEASE 
Non-alcoholic fatty liver disease (NAFLD) is associated with a multitude of other 
pathological conditions ranging from indolent fat storage to progressive cardiovascular, 
metabolic and/or liver and kidney disease. NAFLD is also associated with an elevated 
risk of cancer. Insulin resistance plays a crucial role in the pathogenesis of NAFLD and 
also plays a dominant role in metabolic syndrome. Insulin resistance, along with 
inflammation and elevated levels of circulating mediators such as lipids, hormones, and 
other substances, are thought to be the underlying causes of NAFLD. Figure 2 shows the 
key pathogenic pathways involved in NAFLD.  
 
Figure 2: Key Pathogenic Pathways Involved In NAFLD (Petta, et al., 2016). 
Systemic insulin resistance reduces adiponectin and increases leptin concentrations, while 
adipose tissue lipolysis is not suppressed (as shown with the “//’’ symbol), despite high 
circulating insulin levels, and plasma FFA concentration is increased.  
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Physiological Conditions 
Under normal physiological conditions, the liver does not serve as a storage depot 
for fat, and thus, the steady state concentration of hepatic triglycerides is normally low. 
Nevertheless, there is significant movement of triglycerides and free fatty acids (FFA) in 
and out of the liver during feeding and fasting.   
In the fed state, dietary fatty acids are absorbed in the intestines, packed into 
chylomicrons, which are absorbed into the lymphatics and later enter the blood stream 
where they are transported to, and localize in, adipose tissue (70%) and the liver (30%).  
In situations of excess carbohydrates and hyperinsulinemia, lipogenesis, the production of 
lipids, also occurs in the liver. In the liver, fatty acids may be converted into other lipid 
species and packed into very low density lipoproteins (VLDL) and exported into the 
bloodstream. In the fasting state, fatty acids are released from the adipocytes into the 
bloodstream and travel to the liver where they are again packaged into VLDL and 
released into the bloodstream or oxidized by the mitochondria. Figure 3 shows the 
mechanisms of lipid metabolism and dysregulation in hepatocytes with NAFLD. 
		 	12		
 
Figure 3: Lipid Metabolism And Dysregulation In Non-Alcoholic Fatty Liver 
Disease (Kawano & Cohen, 2013). In NAFLD patients, enhanced acquisition of fatty 
acids through uptake and rates of de novo lipogenesis are not compensated by possible 
increases in rates of fatty acid oxidation or higher production rates of VLDL particles. 
Pink arrows denote the increases and decreases that occur in NAFLD. 
 
Pathological Conditions 
The accumulation of triglycerides in the liver arises from an imbalance of fatty 
acid uptake or de-novo fatty acid synthesis and its removal,  (i.e.VLDL use or 
mitochondrial oxidation). Initial theories for how this develops included a theory based 
on a “2-hit hypothesis” (Kawano & Cohen, 2013). The “first hit” is hepatic steatosis, 
developed due to accumulation of triglycerides in hepatocytes, which over a long period 
of time, seems to trigger the “second hit” with inflammatory cytokines/adipokines, 
mitochondrial dysfunction and oxidative stress leading to steatohepatitis, inflammation of 
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hepatocytes due to fat accumulation, and fibrosis (Dowman, Tomlinson, & Newsome, 
2009). Figure 4 illustrates the chain of events of the 2-hit theory.  
 
Figure 4: Illustration Of The 2-Hit Hypothesis Of NAFLD (Dowman, Tomlinson, & 
Newsome, 2009). Steatosis represents the ‘first hit’, which then sensitizes the liver to 
injury mediated by ‘second hits’, such as inflammatory cytokines, adipokines, oxidative 
stress and mitochondrial dysfunction, leading to steatohepatitis and fibrosis. The presence 
of high levels of oxidative stress reduces the ability of mature hepatocytes to proliferate, 
resulting in reduced endogenous liver repair. 
  
However, recent studies have shown an increasingly important role of FFA as a potential 
culprit of liver injury as seen in mice models (Liu, Han, Zhu, & Yu, 2016). In obese and 
insulin resistant patients, there is an increased influx of FFA to the liver. Upon entry into 
the hepatocytes, the FFA undergo beta-oxidation or are esterified with glycerol and 
converted into triglycerides. The stored triglycerides in the hepatocytes lead to fat 
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accumulation in the liver. More recent studies have also shown that FFA entry into 
hepatocytes alone can lead to hepatic toxicity and inflammation by increasing oxidative 
stress levels, and triglyceride formation may be a way that the hepatocyte protects itself 
from FFA (Feldstein, et al., 2004). Additionally, it has been shown that oxidative stress 
not only triggers inflammation, it also seems to prevent the hepatocytes from 
proliferating (Cichoz-Lach, 2014). In a healthy liver, hepatic death triggers proliferation 
of new hepatocytes. However, in NAFLD patients, the regeneration capabilities of the 
liver seem to be impaired. Since hepatic regeneration is impaired, fibrosis and thus 
cirrhosis development occurs to a larger extent (Feldstein, 2004).  
Insulin Resistance 
 Insulin resistance, recently recognized as a strong predictor of disease in adults, 
has become the leading element of the metabolic syndrome.. The condition exists when 
insulin levels are higher than expected relative to the level of glucose.  It is defined where 
a normal or elevated insulin level fails to achieve normal glucose metabolism. This refers 
to impaired sensitivity to insulin mediated glucose uptake. 
Compensatory hyperinsulinemia, as the name may suggest, occurs when pancreatic β cell 
secretion increases to maintain normal blood glucose levels as a result of insulin 
resistance in muscle and adipose tissue (Wilcox, 2005). 
Under normal physiological conditions, insulin binding to the insulin receptor in 
muscle and adipose results in the phosphorylation of several substrates. Ultimately the 
activation of protein kinase B by phosphorylation results in the translocation of the 
glucose transporter 4 (GLUT4) containing vesicles to the plasma membrane, GLUT4 
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facilitates the uptake of glucose when insulin concentration is high.  It is known as the 
insulin-sensitive glucose transporter as its translocation to the plasma membrane is 
insulin-mediated. GLUT4 is postulated to exist only in adipose tissue and striated muscle, 
which are responsible for 50-80% of glucose transportation in the body (Huang & Czech, 
2007). 
 At the same time, in healthy individuals, insulin suppresses lipolysis, in the 
adipose tissue, whereas glucagon stimulates lipolysis. Lipolysis is the process by which li 
triglycerides are hydrolyzed into glycerol and fatty acids. Hormones that induce lipolysis 
are glucagon, epinephrine, ghrelin, growth hormone, cortisol, and testosterone among 
others. Insulin, on the other hand, inhibits lipolysis in adipocytes and thereby does not 
result in an increase of FFA in the blood (Chakrabarti, et al., 2013). 
However in the case of NAFLD and cases of type 2 diabetes mellitus who have 
varying degrees of insulin resistance, lipolysis suppression in the adipocytes is impaired 
resulting in an increased efflux of FFA into the bloodstream (Lewis, Carpentier, Adeli, & 
Giacca, 2002). Additionally, in patients with NAFLD and type 2 diabetes, GLUT4 
transporter expression is decreased (Shan, Chen, Zhu, Jiang, & Zhou, 2011). The 
hyperinsulinemia associated with insulin resistance thus results in lipid accumulation in 
hepatocytes, while at the same time inhibiting beta-oxidation of FFAs in the liver leads to 
further lipid accumulation in hepatocytes.  
Inflammation and Steatohepatitis 
The presence of chronic hepatic inflammation is closely linked to the steatosis 
(ballooning) of the hepatocytes and mediated by the activation of NF-kB signaling 
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pathways. In mouse models on high-fat diets, steatosis resulting from the increased fat 
led to an increased activation of the NF-kB pathway associated with increased levels of 
inflammatory cytokines such as TNF-alpha, interleukin 6, interleukin 1-beta, and 
activation of the Kupffer cells (Cai, et al., 2005). The NF-kB pathway can be directly 
activated by an excess of FFAs as mentioned above and lead directly to inflammation. 
Thus, one can understand why central obesity leading to increased FFA in hepatocytes 
would lead to inflammation and eventually NAFLD and NASH. The chain of events is 
shown in Figure 5. 
 
 
Figure 5: Progression Of Increased FFA Uptake In Hepatocytes To The 
Development Of NASH (Dowman, Tomlinson, & Newsome, 2009). Proposed 
pathogenesis of NASH. The likelihood of progression to advanced NASH/cirrhosis 
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results from a complex interplay between genetic predisposition and the mechanisms 
described   
 
Increased levels of both serum and hepatic levels of TNF-alpha exist in patients 
with NASH, and these increased levels correlate histologically with the severity of liver 
damage. Additionally, TNF-alpha, a cytokine, has been shown to promote insulin 
resistance. Conversely, in situations where TNF-alpha is inhibited, results show an 
improvement in liver fibrosis and insulin resistance (Dowman, Tomlinson, & Newsome, 
2009). 
 A cytokine derived from adipose tissue called adiponectin has also been shown to 
play a role in the pathogenesis of NAFLD. Adiponectin secretion from adipocytes and 
concentration is inversely proportional to body fat content in healthy people, and 
adiponectin secretion is reduced in patients with NAFLD. Adiponectin levels are also 
inversely proportional to insulin resistance in patients. Its expression is primarily 
determined by adipocyte size and activity. It is seen as a protective adipocytokine that is 
involved in the regulation of glucose and lipid metabolism (Nigro, et al., 2014). 
Moreover, adiponectin is involved in the regulation of inflammation by inhibiting the 
NF-kB pathway, a proinflammatory signaling pathway leading to increased 
proinflammatory cytokines. Adiponectin’s anti-inflammatory effects also include 
inhibition of TNF-alpha production in macrophages, which suppresses adiponectin 
production (Berg, Combs, & Scherer, 2002). Adiponectin levels in the body can be useful 
in distinguishing NASH from simple steatosis since it can be a signal of inflammation 
verses simple ballooning due to fat accumulation (Lemoine, et al., 2009).  
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 Hepatic inflammation can be further aggravated by oxidative stress and 
mitochondrial dysfunction. Under normal physiological conditions, the mitochondria in 
hepatocytes carry out the process of beta-oxidation in which fatty acid molecules are 
broken down. However, in NAFLD and NASH, the hepatocyte is overwhelmed by the 
concentration of FFA giving rise to reactive oxygen species (ROS). ROS induces 
oxidative stress and activates inflammatory pathways resulting in mitochondrial damage 
(Day, 2002). Patients with NASH have been observed with abnormal mitochondrial 
structure and a reduction in mitochondrial cellular respiration activity (Pérez-Carreras, 
2003). Additionally, patients with NASH have an elevated expression of the fatty acid 
oxidizing enzyme, cytochrome P450 2E1. Overexpression of this enzyme has been 
associated with oxidative stress, insulin resistance, and hepatic fat accumulation 
(Kathirvel, Morgan, French, & Morgan, 2009). 
Diagnosis of NAFLD 
 NAFLD and NASH are difficult to diagnose, and many people have NAFLD or 
NASH without knowing it. There are few distinguishing symptoms and patients can be 
asymptomatic over a long period of time. Often times, the few symptoms that may exist 
are non-specific such as right upper-quadrant discomfort or fatigue. Moreover, not all 
patients show signs of increased liver enzymes, such as elevated serum aminotransferase 
levels indicative of liver injury. Elevated levels are only typically seen in 50-80% of 
patients with NASH (McCullough, 2002). The increase in liver enzymes is typically 
around 1.5 times the upper limit of the normal (Sattar, N., Forrest, & Preiss, 2014).  The 
difficulty in making this diagnosis leaves gastroenterologists and hepatologists with more 
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questions than answers when it comes to deciding which patients with NAFLD need a 
biopsy and which would benefit from potential pharmacologic agents. Due to the large 
number of patients living with NAFLD, 80-100 million in the United States alone, it is 
simply not feasible to perform a liver biopsy on all the patients (Browning, et al., 2004). 
However, liver biopsy is the golden standard for diagnosing and staging of NASH. The 
presence of specific histological signs of NASH on an initial biopsy is the predominant 
indicator of development and progression of NASH to liver fibrosis. Liver fibrosis, in 
turn, leads to numerous other clinical issues, including cancer. Therein lies the 
importance of a liver biopsy in prognosis and management of potential future 
complications should NASH progress into liver fibrosis. In some cases, however, NASH 
is also diagnosed incidentally during imaging or surgery. The diagnosis of NASH 
through liver biopsies follows a rather standard procedure. The liver tissue is stained with 
a hematoxylin and eosin (H&E) and evaluated by a histopathologist. The tissue is then 
examined for characteristic patterns of steatosis, inflammation and hepatocellular 
ballooning in the absence of a history of significant alcohol consumption. Figure 6 shows 
examples of histological tissue from mild steatosis and its progression. Different stages of 
NAFLD are given a NAFLD activity score (NAS) based on three parameters: steatosis 
grade, inflammation, and ballooning. Figure 7 outlines the scoring system. It is worth 
mentioning, however, that liver biopsies also have their shortcomings. They are often 
expensive, subjective, and associated with risks to the patient.  
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Figure 6: Histological Slides On Mild Steatosis And Its Progression (Kleiner, et al., 
2005). 
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Figure 7: NAFLD Activity Score (adapted from Kleiner, et al., 2005).  
Progression of NAFLD and Complications 
  Overall the risk of progression to cirrhosis in patients with NAFLD is low with a 
population-based study of 417 adult patients that were matched based on their baseline 
characteristics demonstrating 3.1% and a mean 7.6 year follow-up (Dam-Larsen, et al., 
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2009). The risk of progression of NAFLD and NASH to end-stage liver disease is based 
upon the severity of the liver histology seen from the liver biopsy and described by the 
NAS. The majority of patients with NAFLD have simple steatosis, but around 30% will 
develop NASH and are thus at a greater risk of end-stage liver disease and liver failure, 
potentially requiring liver transplantation (Matteoni, et al., 1999). Studies have shown 
that patients with simple steatosis have a risk of 0-4% of progression to cirrhosis. In 
contrast, NASH patients have a 25% risk of developing cirrhosis over 9 years (Ekstedt, et 
al., 2006). The rate of progression is determined by the extent of liver injury, measured 
by the extent of fibrosis. Patients with NASH, but with no fibrosis have a significantly 
lower risk of progressing towards cirrhosis than patients with NASH with advanced 
fibrosis. Progression to cirrhosis is not identical in all patients and highly dependent on 
other factors, such as the presence of glucose intolerance and type 2 diabetes (Sanyal, et 
al., 2006).  
Once cirrhosis has developed, the risk of further complications, such as portal 
hypertension, is significantly increased (Sauerbruch & Trebicka, 2014). Thus, compared 
with healthy individuals of the general population, patients with NAFLD have a lower 
than expected survival rate (Adams, Sanderson, Lindor, & Angulo, 2005). Table 3 shows 
the extent of fibrosis as a predictor for liver-related complications, death, and overall 
mortality. 
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Table 3: Fibrosis As A Predictor For Liver-Related Complications, Death, And 
Overall Mortality (Sanna, Rosso, Marietti, & Bugianesi, 2016).  
 
Current Treatment Options 
 After many years of research, there are still no approved pharmacologic agents or 
treatments for the non-alcoholic steatohepatitis. Although there is a clear unmet clinical 
need and high scientific interest, the gold standard for treatment of NASH at the present 
is lifestyle modification with a combination of weight loss and exercise. Figure 8 shows 
the current treatment algorithm for patients with NAFLD.   
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Figure 8: Current Treatment Algorithm For Patients With NAFLD (Lazaridis & 
Tsochatzis, 2017). 
The challenge in finding a suitable therapy lies in the lack of understanding of the 
pathogenesis and pathophysiology of this disease. There are many associated risk factors 
of NAFLD that can lead to the histological alterations seen in NAFLD patients. Each of 
these causes can, therefore, potentially be an effective target for pharmacologic agents. 
Currently, insulin sensitizers are one category of drugs used to combat the insulin 
resistance seen in NAFLD and NASH. This class of drugs called glitazones which 
includes antidiabetics such as pioglitazone and rosiglitazone.  The use of pioglitazone in 
patients with NASH was studied in Pioglitazone versus Vitamin E versus Placebo for the 
Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial. 
This was a phase 3, multicenter, randomized, placebo-controlled, double-blind clinical 
trial of pioglitazone or vitamin E for the treatment of adults without diabetes who had 
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biopsy-confirmed nonalcoholic steatohepatitis. Patients consuming more than 20g of 
alcohol per day were excluded from the study (Sanyal, et al., 2010). 
The clinical trial PIVENS studied 247 patients consisting of three groups. The 
three groups were well matched with respect to demographic characteristics, clinical and 
laboratory data, and activity scores for nonalcoholic fatty liver disease (Sanyal, et al., 
2010). Of the 247 patients, 80 patients were randomized to take 30 mg/day of 
pioglitazone in one arm versus 84 patients to vitamin E (800 IU/day) versus 83 patients to 
placebo for two years (Sanyal, et al., 2010). Pioglitazone improved all individual 
histological features, except fibrosis, and was able to achieve resolution of steatohepatitis 
versus placebo. Additionally, the improvements in hepatic tissue histology were 
correlated with a similar reduction of alanine transaminase (ALT) and partial 
improvement in insulin resistance (Ratziu, Bellentani, Cortez-Pinto, Day, & Marchesini, 
2010). Glitazones, such as pioglitazone and rosiglitazone, have been shown to improve 
the insulin resistance seen in adipose tissue related to the reduction in steatohepatitis as 
well as necroinflammation (Gastaldelli, et al., 2009). A longer study for three years of 
rosiglitazone, however, did not show a hepatic histological improvement beyond the first 
year.  Besides the short-term results from the glitazones, cardiovascular safety concerns 
and reports of adverse events showing a significant increase in myocardial infarctions and 
cardiovascular death in patients taking rosiglitazone, have also hindered their use (Nissen 
& Wolski, 2007). 
Vitamin E has long been looked at as a potential treatment for NAFLD, although 
with some serious safety concerns. Vitamin E is a fat-soluble compound present in the 
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cell membrane bilayer of cells that protects the cell from free radical-induced oxidative 
damage (Soden, et al., 2007). Its efficacy was evaluated in the PIVENS trial where 800 
IU/day of Vitamin E resulted in a significant decrease in NASH, measured by liver 
biopsy, in 36% of patients vs. 21% in the placebo group. The reduction in the liver 
enzyme alanine transaminase (ALT) was correlated with the histological improvement 
seen in patients taking Vitamin E in the trial. Concerns about Vitamin E exist due to 
cases of increased mortality, hemorrhagic stroke, and prostate cancer(Bjelakovic, 
Nikolova, Gluud, Simonetti, & Gluud, 2007). Due to the safety concerns, additional 
studies should be performed to take a closer look at the overall safety and efficacy profile 
of Vitamin E as a treatment for NASH.  
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THE ROLE OF A GLP-1 RECEPTOR AGONIST (GLP-1 RA) IN NASH 
 
Mechanism of Action in the Pancreas 
 
GLP-1 is released from L cells in the intestine in response to glucose after eating 
and lowers the concentrations of glucose by stimulating secretion of insulin from the 
pancreatic beta cells. The stimulation of insulin secretion however, is strictly glucose 
dependent. Thus, during fasting, human GLP-1 is not activated.  This has made the GLP-
1 receptor agonist analogue a popular choice for the treatment of diabetes as its glucose-
dependent mechanism of action decreases the likelihood of potentially fatal 
hypoglycemic events (Kuhre & Albrechtsen, 2014). Figure 9 illustrates the endocrine 
pathway of GLP-1.  
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Figure 9: GLP-1 Endocrine Pathway (Holst, 2007). GLP-1 secretion by the L 
cells are stimulated by nutrients in the gut and released into the capillaries of the lamina 
propria. only to be broken down by dipeptidyl peptidase IV (DPP-IV) leading to about 
25% of secreted GLP-1 to reach the liver. In the liver, GLP-1 is further degraded leaving 
about 10-15% of the original GLP-1 secretion in the bloodstream.  
 
In addition to the insulinotropic effects of the GLP-1 RA, its ability to inhibit 
glucagon secretion is also crucial to its anti-diabetic function as it results in a decrease in 
hepatic glucose production and a decrease in lipolysis (Hvidberg, Nielsen, Hilsted, 
Ørskov, & Holst, 1994). However, GLP-RA’s inhibition of glucagon secretion is most 
likely not a result of GLP-1’s effects directly on the glucagon secreting alpha cells as the 
alpha cells have not been shown to have GLP-1 receptors. The exact mechanism of action 
of GLP-1 on alpha cells is still yet to be determined.  
		 	29		
Mechanism of Action in the Stomach 
 One of the many effects of GLP-1 is also its action on the stomach and its effect 
on gastric emptying. . Gastric emptying is the natural process of emptying the stomach’s 
content into the intestines.  It is a coordinated process in which intense peristaltic 
contractions in the antrum of the stomach push chyme, processed food, into the pylorus 
of the stomach. Under physiological conditions, this occurs a few hours after eating.  
Many factors affect the rate of gastric emptying in individuals.  Some of these factors 
include gastric volume, liquid vs. solid food, types of food, hormonal factors, neural 
factors, drugs, disease states, and many more (Cheng, 2006). A deceleration of gastric 
emptying has been seen in both patients with diabetes as well as healthy individuals 
taking a GLP-RA (Meier, et al., 2003). A number of studies have investigated the 
relationship between a faster-than-normal rate of gastric emptying and development of 
obesity (Janssen, et al., 2011).  
The mechanism of action of GLP-1 on gastric emptying is not well understood 
but seems to be naturally mediated. GLP-1 is postulated to inhibit gastropancreatic 
function by inhibiting central parasympathetic outflow (Andrews, et al., 2007). This was 
shown in patients that underwent truncal vagotomy and lost the effects of the GLP-1.  
Signaling via the vagus nerve was investigated in 20 truncally vagotomized subjects with 
pyloroplasty, surgery to widen the opening in the lower part of the stomach (pylorus) so 
that stomach contents can empty into the duodenum. There were 10 matched healthy 
controls. Subjects received GLP-1 (7-36 amide) or saline infusions during and after a 
standardized liquid mixed meal and a subsequent ad libitum meal. Despite no effect on 
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appetite sensations, GLP-1 significantly reduced ad libitum food intake in the control 
group but had no effect in the vagotomized group (Plamboeck, et al., 2013). 
Thus, the effects of the GLP-1 on gastric emptying seem to be neurally mediated 
and decrease with continued exposure to GLP-1. It is worthy of mention that the decrease 
in effects of GLP-1 with continued exposure do not apply to its insulin secreting or 
glucagon inhibiting effects (Tong & Dalessia, 2014). Its continued exposure and resulting 
attenuation also seem to explain the improvement of nausea in patients that are on a GLP-
1. This is further described in the safety overview (Collective, 2013). Figure 10 shows a 
summary of the central and peripheral effects of the GLP-1.  
  
Figure 10: Central and Peripheral Effects of GLP-1 (Tong & Dalessio, 2014).  
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Mechanism of Action in the Brain 
The hypothalamus, specifically the arcuate nucleus (ARC), is thought to be the 
predominant area of appetite regulation in the body (Minor, Chang, & Cabo, 2009). Arc 
orexigenic (appetite increasing) and anorectic/anorexigenic (appetite suppressing) 
neurons present in the ARC are known to respond to many ingestive signals include, 
GLP-1. Receptors for GLP-1 are present on the orexigenic neuropeptide Y/agouti-related 
peptide (NPY/AgRP) neurons, and the anorexigenic proopiomelanocortin (POMC) 
neurons (Dailey & Moran, 2013). GLP-1 stimulates electrical activity of hypothalamic 
POMC neurons by activating protein kinase A leading to an increase in Ca+2 current (Ma, 
Brunin, & Ashcroft, 2007). The activation of the POMC neurons by GLP-1 result in 
appetite suppression. In obese patients, there has been shown to be a lack of POMC 
neuronal firing (Ma, Brunin, & Ashcroft, 2007). See Figure 11 for an illustrative version 
of the role of GLP-1 in appetite suppression. 
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Figure 11: Melanocortin Pathway (Walley, Asher, & Froguel, 2009). NPY/AgRP 
neurons have axon terminals that release GABA (an inhibitory neurotransmitter) to 
suppress the POMC neurons 
 
 
		 	33		
 
Figure 12: Peripheral Hormones Modulating Appetite in Brain Centers (Camilleri, 
2015).  Gastrointestinal and fat-derived hormones stimulate specific areas of the 
hypothalamus and brainstem that sense nutrients, and coordinate the response to hunger 
and the intake of food. Red arrows express inhibition. Green arrows exhibit activation. 
 
GLP-1 Receptor Agonists as Pharmacologic Agents in Type 2 Diabetes 
 
Due to the glucose-lowering capabilities of the GLP-1 receptor agonists, patients 
with type 2 diabetes have seen a significant benefit (Holmes, Browning, Tong, Qualls-
Creekmore, & Travagli, 2009). Due to its properties as an incretin, mediating insulin 
secretion, as mentioned previously, many pharmacological agents treating type 2 diabetes 
are GLP-1RAs. Extensive research and publications have been made on the topic of 
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GLP-1RA within type 2 diabetes and will not be further discussed in relation to this 
literature review. 
GLP-1 Receptor Agonists as Pharmacologic Agents in Obesity 
As mentioned previously, liraglutide, is the only GLP-1 RA that is FDA- 
approved for use in weight management of obesity for patients with a BMI over 30 or 
BMI over 27 with weight-related co-morbidities. Liraglutide for obesity was studied as 
part of a development program, called SCALE™, investigates liraglutide 3 mg for weight 
management. SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) consists 
of four, placebo-controlled, multinational trials called: SCALE™ Obesity and 
Prediabetes, SCALE™ Diabetes, SCALE™ Sleep Apnea and SCALE™ 
Maintenance.11-14 The trials include more than 5,000 people who are overweight (BMI 
≥27 kg/m2 ) with comorbidities such as hypertension, dyslipidemia, obstructive sleep 
apnea (OSA) or type 2 diabetes or who have obesity (BMI ≥30 kg/m2 ), with or without 
comorbidities. The studies all involved a reduced-calorie diet and increased physical 
activity (Pi-Sunyer, et al., 2015). In addition to recommended diet and physical activity, 
liraglutide consistently resulted in a 4 to 6 kg weight loss, with a greater proportion of 
patients achieving at least 5 and 10% weight loss compared with placebo. The most 
common adverse effects were gastrointestinal and primarily occurred early in the 
treatment course (Mehta, Marso, & Neeland, 2016). 
GLP-1 Receptor Agonists and Cardiovascular Disease 
Diabetes mellitus is a major risk factor for the development of cardiovascular 
disease, independently conferring a 2-fold excess risk of coronary heart disease and 
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stroke (Martín-Timón, 2014). Cardiovascular events remain the leading cause of death 
and mortality among diabetics, and the burden of cardiovascular disease in this 
population has only gotten greater over the years (Leon, 2015). Additionally, obesity 
further exacerbates the risk of cardiovascular disease in diabetic patients.  
Tight glycemic control reduces the microvascular complications associated with 
diabetes mellitus. However, macrovascular benefits of invasive therapy have been 
difficult to show across clinical trials (Smilowitz, Donnino, & Schwartzbard, 2014). 
Microvascular complications include diabetic nephropathy, neuropathy, and retinopathy 
while macrovascular complications include coronary artery disease, peripherial artery 
disease, and stroke. Figure 13 gives an overview of the macrovascular and microvascular 
complications. Thus, treatment of cardiovascular risk in diabetics is multi-fold with a 
focus not only on glycemic control but also on blood pressure reduction, lipid 
management, weight loss, and increased physical activity.  
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Figure 13: Macrovascular and Microvascular Complications of Diabetes. (Cefalu): 
 
Given the increased risk of cardiovascular disease in diabetic patients, antidiabetic 
therapeutics, such as GLP-1 receptor agonists, have been required by new to market 
antidiabetics. The aim of the FDA Guidance for Industry is to establish the safety levels 
of newly developed antidiabetic drugs for type 2 diabetes treatment. To that end, 
sponsors should demonstrate that the therapy will not result in an unacceptable increase 
in cardiovascular (CV) risk (Schnell, et al., 2016). 
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As a result of the guidance from the FDA on Cardiovascular Outcome Trials 
(CVOTs) for new antidiabetics, GLP-1 RAs have been studied in patients with type 2 
diabetes who are at a risk for cardiovascular disease. Liraglutide, a GLP-1 RA approved 
for use to treat patients with type 2 diabetes and obesity, was shown to significantly 
reduce cardiovascular risk in patients with type 2 diabetes (Marso, et al., 2016). 
LEADER®, The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results trial (LEADER) (NCT01179048), was the first clinical trial in which 
the findings showed statistically significant lower risk of a GLP-1 in a CVOT as 
compared to placebo (Kalra, 2016). Table 4 shows a summary of the results of the 
LEADER trial. 
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Table 4: LEADER Results Summary (Kalra, 2016). 
 
In LEADER, the primary outcome measured and evaluated was a composite of 
three major adverse cardiovascular events (three-point MACE), defined as first 
occurrence of death from cardiovascular causes, non-fatal myocardial infarction (MI), or 
non-fatal stroke.  The trial was a multicenter double-blinded study that included 9340 
patients in 32 countries.  Of the 9340 patients, 4668 were randomized to liraglutide and 
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4672 to placebo with standard of care. The demographic and clinical characteristics of the 
patients were similar in both groups. The majority of patients had established 
cardiovascular disease (6764 patients), chronic kidney disease of stage 3 or higher 
(2307), or both (1473).    
The trial resulted in a 13% reduction in the primary outcome, the composite of the 
three events, and a 22% reduction in cardiovascular death (Kalra, 2016). Liraglutide was 
shown to have a significant effect on body weight (2.3 kilograms weight loss vs. 
placebo), systolic blood pressure (1.2 mm Hg lower than placebo), lipids, and seems to 
impede and rather stabilizes the progression of atherosclerotic plaques. These significant 
findings led to further investigation of liraglutide and its role in reducing the risk of 
cardiovascular disease beyond just glycemic control and weightloss. 
GLP-1 Receptor Agonists and Inflammation 
 The LEADER trial, and others (Armstrong, et al., 2016), have shown the anti-
inflammatory effects of liraglutide may be important in reducing the risk for 
cardiovascular disease and non-alcoholic fatty liver disease. It was hypothesized in the 
LEADER trial that the decrease in cardiovascular risk was partially a result of the 
stabilization of atherosclerotic plaques resulting in the decrease of chronic inflammation. 
Low grade inflammation of the endothelium is an early event in the pathogenesis of 
atherosclerotic cardiovascular disease. Liraglutide was associated with reduced 
inflammatory responses to TNF-alpha and lipopolysaccharides (LPS) (Krasner, Ido, 
Ruderman, & Cacicedo, 2014). 
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 The anti-inflammatory effects of liraglutide, however, had been previously 
studied in mouse models with chronic inflammation in the brain, the liver, and 
vasculature (Parthsarathy & Hölscher, 2013). After the injection of liraglutide, these areas 
showed a decrease in inflammatory markers such as IL-6, IL-12, and IL-1 beta. It is this 
remarkable decrease in inflammatory markers shown in the LEADER trial as well as 
other studies that make liraglutide a good potential candidate for other diseases that 
involve chronic inflammation such as Alzheimer’s Disease and NAFLD.  
GLP-1 Receptor Agonists in the Treatment of NASH   
It is no wonder that when evaluating treatment options for NAFLD and NASH 
that a GLP-1 RA becomes an attractive option for treatment. The pathogenesis and 
pathophysiology of NAFLD is such that key drivers of the development of the disease 
can potentially be addressed by this pharmacologic agent. Moreover, NAFLD, diabetes, 
and cardiovascular disease are manifestations and/or risk factors of metabolic syndrome, 
which is a term coined by the World Health Organization to identify people with greater 
risk of cardiovascular disease. A diagnosis of metabolic syndrome requires that patients 
have one of the following: diabetes, impaired glucose tolerance, impaired fasting glucose, 
and/or impaired insulin resistance. Moreover, patients should also have two of the 
following conditions: a high waist to hip ration, dyslipidemia, high blood pressure, and/or 
microalbuminuria (Alberti & Zimmet, 1998). Figure 14 shows the manifestations of the 
metabolic syndrome.  
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Figure 14: The Metabolic Syndrome That Is A Result Of The Risk Factors In This 
Figure (Pollack, 2015).    
Therefore, it is logical to think that treating the risk factors of these conditions can 
lead to an overall benefit or reduction of risk in all of them. The multi-faceted benefits of 
GLP-1 receptor agonists in glycemic control, anti-inflammatory effects, decrease in body 
weight, and improvement of dyslipidemia seem to ameliorate many of the putative root 
causes of NAFLD. Moreover, as the rate in fibrosis decreases due to a treatment of the 
root causes of NAFLD, the liver has the opportunity to regenerate at a faster rate than the 
rate of injury resulting in an overall improvement in fibrosis. This ultimately leads to a 
decrease in the complications of liver disease and can hopefully decrease the number of 
liver transplants due to NAFLD and NASH.   
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 Further evidence to support the potential use of a GLP-1 in NASH was presented 
in a clinical trial that was a multicenter, double-blinded, randomized, placebo-controlled 
trial with 52 patients performed in the United Kingdom to investigate the effects of a 
GLP-1 RA, liraglutide, in patients with NASH. The Liraglutide safety and efficacy in 
patients with non-alcoholic steatohepatitis (LEAN): assessed subcutaneous injections of 
liraglutide (1.8 mg) as compared with placebo in patients that were overweight and 
showed clinical evidence of NASH. The primary endpoint measure was resolution of 
definite NASH with no worsening in fibrosis from baseline to end of treatment (48 
weeks), as assessed centrally by two independent pathologists. Analysis was done by 
intention-to-treat analysis, which included all patients who underwent end-of-treatment 
biopsy. Twenty-six patients were randomized to liraglutide and 26 patients were 
randomized to the placebo arm. Liraglutide met the predefined primary endpoint and led 
to resolution of NASH in nine (39%) of 23 patients that finished the trial in the liraglutide 
arm in comparison to two (9%) of 22 patients in the placebo arm. Study withdrawal rates 
were the same in both treatment groups and had no effect on the primary endpoint 
(Armstrong, 2016). 
Safety Profile of GLP-1 Receptor Agonist 
 
 The most common side-effects for most GLP-1RAs on the market are generally 
the dose-dependent gastrointestinal side effects including nausea, vomiting, and diarrhea. 
Around 5-10% of patients abandon therapy for these reasons.  However, overall patient 
satisfaction is high as these effects diminish with time (Collective 2013). 
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 As GLP-1 RA mediated insulin secretion is glucose-dependent, hypoglycemia in 
patients taking a GLP-RA is uncommon. 
 The main safety concerns rise from the pleiotropic properties of GLP-1 in the 
pharmacologically administered doses due to the extensive presence of GLP-1 receptors 
in the body as mentioned earlier.  Heart rate increases of 2-4 beats per minute have been 
reported that potentially could have adverse long-term consequences.  Increase in 
pancreatic enzymes are commonly observed along with cases of pancreatitis.  Liraglutide, 
in particular, is contra-indicated with a black-box warning by the FDA for thyroid C-cell 
cancers seen in rodent studies as part of the drug development program for liraglutide 
(Collective, 2013). 
 Longer term studies such as LEADER, mentioned earlier, have gathered more 
long-term safety data on liraglutide, and  have shown no difference between the placebo 
arm and the liraglutide arm with regards to serious adverse events (SAEs) and pre-
specified SAEs such as pancreatitis and neoplasms (Kalra, 2016). 
 Overall, as with any pharmacological agent, one must weigh the risks and benefits 
before concluding if the treatment option is suited for patients.  
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CONCLUSION 
	
Given the safety and efficacy of liraglutide, and potentially other GLP-1 receptor 
agonists, in treating a variety of related conditions within the metabolic syndrome, there 
seems to be a potential pharmacologic agent that can treat NALFD and NASH. The 
approval of such an agent will have remarkable effects on the treatment paradigm of 
NAFLD and improve patient lives. Based on the review of the clinical trials and studies 
presented, there seems to be a significant amount of evidence that would support the 
hypothesis that GLP-1 RAs, and more specifically liraglutide, could be potential 
pharmacological agents in treating NAFLD and NASH.  However, a more structured and 
longer term clinical program are necessary to confirm this hypothesis. The great unmet 
need of NAFLD and NASH require that more testing and research be dedicated to 
accelerating the use of GLP-1 RAs and other potential therapeutics to enhance and better 
the lives of patients worldwide.  
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